Leitlinienorientierte Therapie des Mammakarzinoms: Kontroversen in der individuellen Betreuung

ZUSAMMENFASSUNG

Evidenzbasierte Leitlinien von Fachgesellschaften sowie Konsensusgespräche auf internationalen Kongressen sind häufig Grundlage für Therapieentscheidungen. Wenn sie in ihrer Bedeutung als Empfehlung richtig eingeschätzt werden, können sie für ein integratives Behandlungskonzept als wertvolle Orientierungshilfe dienen. Neben der Nutzen-Risiko-Analyse etablierter Therapiestrategien ist auch die Berücksichtigung innovativer diagnostischer und therapeutischer Strategien für eine individuelle Therapieplanung erforderlich.

SUMMARY

Evidenced based guidelines of international or national conventions frequently are basis for therapy decisions. If they are assessed correctly by her meaning as recommendations they can serve for an integrated treatment concept as valuable help. The analysis of established therapy strategies is necessary for an individual therapy planning, but also requires the considering of innovative diagnostic and therapeutic strategies.

Schlüsselwörter

Evidenzbasierte Leitlinien - Mammakarzinom - antihormonelle Therapie - adjuvante Therapie - palliative Chemotherapie

Key Words

Evidenced based guidelines - breast cancer - antihormons - adjuvant therapy - palliative chemotherapy

Literatur

• 01 Colleoni M. et al . Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.  Brit J Cancer. 2002;  86 (11) 1705-1714
• 02 Darby S. et al . Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women.  BMJ. 2003;  326 (7383) 256-257
• 03 Fisher B. et al . Twenty-year follow-up of randomized trial comparing total mastectomy, total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.  N Engl J Med.. 2002;  347 (16) 1233-1241
• 04 Goldhirsch A. et al . Meeting highlights: updated international expert consensus on the primary therapy of breast cancer.  J Clin Oncol.. 2003;  21 (17) 3357-3365
• 05 International Breast Cancer Study Group (IBCSG) . Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial.  J Natl Cancer Inst.: 2002;  94 (14) 1054-1065
• 06 Jungi W F, Senn H J. Verhinderung von Rezidiven durch adjuvante Chemotherapie.  Onkologe. 1998;  4 740-746
• 07 Levi F. et al . Cancer risk in women with previous breast cancer.  Ann Oncol.. 2003;  14 (1) 71-73
• 08 Maughan T S. et al . Comparison of intermittent and continous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.  Lancet. 2003;  361 (9356) 457-464
• 09 Nooij M A. et al . Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists' preferences.  Eur J Cancer.. 2003;  39 (5) 614-621
• 10 Provenzano E. et al . Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.  Eur J Cancer.. 2003;  39 (5) 622-630
• 11 Recht A. et al . The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.  New Engl. J Med.. 1996;  334 (21) 1356-1361
• 12 Robertson J F. Oestrogen receptor: a stable phenotype in breast cancer.  Br J Cancer.. 1996;  73 (1) 5-12
• 13 Slamon D J. et al . Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med.. 2001;  344 (11) 783-792
• 14 The ATAC Trialists`Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.  Lancet. 2002;  359 (9324) 2131-2139
• 15 Veronesi U. et al . Effect of menstrual phase an surgical treatment of breast cancer.  Lancet. 1994;  343 (8912) 1545-1547
• 16 Veronesi U. et al . Twenty-year follow-up of randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.  N Engl J Med.. 2002;  347. (16) 1227-1232
• 17 Zemzoum I. et al . Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.  J Clin Oncol.. 2003;  21 (6) 1022-1028

Korrespondenzadresse